ArticleGlobal health action2017
ZikaPLAN: Zika Preparedness Latin American Network.
Article in Global health action, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Incidence of Guillain-Barré Syndrome (GBS) in Latin America and the Caribbean before and during the 2015-2016 Zika virus epidemic: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2019Pooled it
- Operational strategies among infectious disease clinical trial sites during pandemics: a scoping review.Trials · 2026Article
- Evaluation of Zika rapid tests as aids for clinical diagnosis and epidemic preparedness.EClinicalMedicine · 2022Article
- A Latin American perspective on neurodiplomacy.Frontiers in medical technology · 2022Article
- The legacy of ZikaPLAN: a transnational research consortium addressing Zika.Global health action · 2021Review
- Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation.Globalization and health · 2021Article
- Target product profile for a dengue pre-vaccination screening test.PLoS neglected tropical diseases · 2021Article
- The Role of Clinical Researchers During COVID-19: Balancing Individual, Scientific, and Social Benefits of Research.Frontiers in public health · 2021Article
- Article
- Guillain-Barré syndrome in times of pandemics.Journal of neurology, neurosurgery, and psychiatry · 2020Article
- Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential.The Lancet. Infectious diseases · 2020Review
- Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review.BMC medicine · 2020Article
- Diagnosis and management of Guillain-Barré syndrome in ten steps.Nature reviews. Neurology · 2019Review
- Impact evaluation of Zika epidemic on congenital anomalies registration in Brazil: An interrupted time series analysis.PLoS neglected tropical diseases · 2019Article
- ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas.Global health action · 2019Article
- Modelling an optimum vaccination strategy against ZIKA virus for outbreak use.Epidemiology and infection · 2019Article
- A consensus statement on birth defects surveillance, prevention, and care in Latin America and the Caribbean.Revista panamericana de salud publica = Pan American journal of public health · 2019Article
- Review
- Asymptomatic Prenatal Zika Virus Infection and Congenital Zika Syndrome.Open forum infectious diseases · 2018Article
- Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report.The Journal of infectious diseases · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 12 institutions in 6 countries.
Funding
Abstract
The ongoing Zika virus (ZIKV) outbreak in Latin America, the Caribbean, and the Pacific Islands has underlined the need for a coordinated research network across the whole region that can respond rapidly to address the current knowledge gaps in Zika and enhance research preparedness beyond Zika. The European Union under its Horizon 2020 Research and Innovation Programme awarded three research consortia to respond to this need. Here we present the ZikaPLAN (Zika Preparedness Latin American Network) consortium. ZikaPLAN combines the strengths of 25 partners in Latin America, North America, Africa, Asia, and various centers in Europe. We will conduct clinical studies to estimate the risk and further define the full spectrum and risk factors of congenital Zika virus syndrome (including neurodevelopmental milestones in the first 3 years of life), delineate neurological complications associated with ZIKV due to direct neuroinvasion and immune-mediated responses in older children and adults, and strengthen surveillance for birth defects and Guillain-Barré Syndrome. Laboratory-based research to unravel neurotropism and investigate the role of sexual transmission, determinants of severe disease, and viral fitness will underpin the clinical studies. Social messaging and engagement with affected communities, as well as development of wearable repellent technologies against Aedes mosquitoes will enhance the impact. Burden of disease studies, data-driven vector control, and vaccine modeling as well as risk assessments on geographic spread of ZIKV will form the foundation for evidence-informed policies. While addressing the research gaps around ZIKV, we will engage in capacity building in laboratory and clinical research, collaborate with existing and new networks to share knowledge, and work with international organizations to tackle regulatory and other bottlenecks and refine research priorities. In this way, we can leverage the ZIKV response toward building a long-term emerging infectious diseases response capacity in the region to address future challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.